The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis
Objectives. Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population. Methods. Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2019/3480732 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566858138517504 |
|---|---|
| author | Xiaoqian Zhou Lei Zhao Ping Yang Yaxi Chen Xiong Z. Ruan |
| author_facet | Xiaoqian Zhou Lei Zhao Ping Yang Yaxi Chen Xiong Z. Ruan |
| author_sort | Xiaoqian Zhou |
| collection | DOAJ |
| description | Objectives. Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population. Methods. Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies. Results. Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR=1.29, 95% CI=1.20 to 1.40, P<0.001) between patients were observed between the two groups. Conclusions. Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments. |
| format | Article |
| id | doaj-art-d95c543eba6d49459616024057a77b7e |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d95c543eba6d49459616024057a77b7e2025-02-03T01:03:05ZengWileyGastroenterology Research and Practice1687-61211687-630X2019-01-01201910.1155/2019/34807323480732The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-AnalysisXiaoqian Zhou0Lei Zhao1Ping Yang2Yaxi Chen3Xiong Z. Ruan4Department of Gastroenterology, The First People’s Hospital of Guiyang, 550000 Guiyang, ChinaCentre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, 400016 Chongqing, ChinaCentre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, 400016 Chongqing, ChinaCentre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, 400016 Chongqing, ChinaCentre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, 400016 Chongqing, ChinaObjectives. Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population. Methods. Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies. Results. Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR=1.29, 95% CI=1.20 to 1.40, P<0.001) between patients were observed between the two groups. Conclusions. Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments.http://dx.doi.org/10.1155/2019/3480732 |
| spellingShingle | Xiaoqian Zhou Lei Zhao Ping Yang Yaxi Chen Xiong Z. Ruan The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis Gastroenterology Research and Practice |
| title | The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis |
| title_full | The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis |
| title_fullStr | The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis |
| title_full_unstemmed | The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis |
| title_short | The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis |
| title_sort | efficacy of flupentixol melitracen in the adjuvant therapy of ulcerative colitis in the chinese population a meta analysis |
| url | http://dx.doi.org/10.1155/2019/3480732 |
| work_keys_str_mv | AT xiaoqianzhou theefficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT leizhao theefficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT pingyang theefficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT yaxichen theefficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT xiongzruan theefficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT xiaoqianzhou efficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT leizhao efficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT pingyang efficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT yaxichen efficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis AT xiongzruan efficacyofflupentixolmelitracenintheadjuvanttherapyofulcerativecolitisinthechinesepopulationametaanalysis |